SCHEMBL6772879

SCHEMBL6772879

CC(=O)OOC1C=CC(O[Si](C)(C)C(C)(C)C)C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7659117 0.84 CA12 (0.35)
SCHEMBL25758895 0.84 CA12 (0.35)
SCHEMBL7441811 0.84 CA12 (0.35)
SCHEMBL14440425 0.84 CA12 (0.35)
SCHEMBL11548963 0.84 CA12 (0.35)
SCHEMBL6772886 0.84 CA12 (0.35)
SCHEMBL25758875 0.84 CA12 (0.35)
SCHEMBL14440399 0.84 CA12 (0.35)
SCHEMBL13573014 0.81
SCHEMBL11548094 0.81

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6673809-B2 INHIBITING RESISTANT NEOPLASM, OR NEOPLASM SUSCEPTIBLE TO RESISTANCE ELI LILLY AND COMPANY 2004-01-06 US disclosed
US-20030216425-A1 Tricyclic compounds as mrp1-inhibitors ELI LILLY AND COMPANY 2003-11-20 US disclosed
EP-1301518-A1 TRICYCLIC COMPOUNDS AS MRP1-INHIBITORS ELI LILLY AND COMPANY (US) 2003-04-16 EP disclosed
WO-2001096346-A1 TRICYCLIC COMPOUNDS AS MRP1-INHIBITORS ELI LILLY AND COMPANY (US) 2001-12-20 WO disclosed